0.<PAGE>
FORM 10-Q
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
[X] Quarterly report pursuant to section 13 or 15(d) of the Securities Exchange
Act of 1934 For the quarterly period ended JUNE 30, 2000 or
[ ] Transition report pursuant to section 13 or 15(d) of the Securities Exchange
Act of 1934 For the transition period from ______ to ______
1-9731
(COMMISSION FILE NO.)
ARRHYTHMIA RESEARCH TECHNOLOGY, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
DELAWARE 72-0925679
(STATE OR OTHER JURISDICTION OF INCORPORATION OR (I.R.S. EMPLOYER
ORGANIZATION) IDENTIFICATION NO.)
1101 SOUTH CAPITAL OF TEXAS HIGHWAY
BUILDING G - SUITE 200
AUSTIN, TEXAS 78746
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICE) (ZIP CODE)
(512) 347-9640
(REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE)
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes X No .
--- ---
As of August 14, 2000 there were 3,337,797 shares of common stock outstanding.
This report consists of 10 pages.
<PAGE>
ARRHYTHMIA RESEARCH TECHNOLOGY, INC.
TABLE OF CONTENTS
FORM 10-Q
June 30, 2000
<TABLE>
<S> <C>
PART I - FINANCIAL INFORMATION.......................................................................................3
Item 1. Financial Statements....................................................................................3
CONSOLIDATED BALANCE SHEETS......................................................................................3
CONSOLIDATED STATEMENTS OF OPERATIONS............................................................................4
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY.......................................................5
CONSOLIDATED STATEMENTS OF CASH FLOWS............................................................................6
SUPPLEMENTAL NOTES TO CONSOLIDATED FINANCIAL STATEMENTS..........................................................7
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations..................7
PART II - OTHER INFORMATION..........................................................................................10
Item 1. Legal Proceedings ......................................................................................10
Item 2. Changes in Securities - none............................................................................10
Item 3. Defaults Upon Senior Securities - none..................................................................10
Item 4. Submission of Matters to a Vote of Security Holders - none..............................................10
Item 5. Other Information - none................................................................................10
Item 6. Exhibits and Reports on Form 8-K - none.................................................................10
SIGNATURES.......................................................................................................10
</TABLE>
2
<PAGE>
ARRHYTHMIA RESEARCH TECHNOLOGY, INC. AND SUBSIDIARY
CONSOLIDATED BALANCE SHEETS
(Unaudited)
<TABLE>
<CAPTION>
June 30, December 31,
ASSETS 2000 1999
----------------- ---------------
<S> <C> <C>
Current assets:
Cash and cash equivalents......................................................................$ 260,832 $ 455,674
Trade and other accounts receivable, net of allowance for doubtful accounts....................
of $33,406 and $83,203................................................................... 2,589,708 1,653,098
Inventories, net............................................................................... 1,200,044 1,082,517
Income tax recoverable......................................................................... 329,408 329,408
Assets held for sale........................................................................... 378,990 0
Other current assets........................................................................... 75,629 52,172
----------------- ---------------
Total current assets......................................................................... 4,834,611 3,572,869
Property and equipment, net of accumulated depreciation of $4,060,868 and $3,699,282............. 3,603,378 3,835,831
Patent and software development costs, net of accumulated amortization of $490,964...............
and $474,712.............................................................................. 115,478 122,887
Goodwill, net of accumulated amortization of $951,548 and $886,603............................... 1,521,778 1,586,723
Deferred leasing costs, net of accumulated amortization of $1,118 and $0......................... 5,592 6,710
Deferred income taxes, net....................................................................... 246,923 423,923
Other assets..................................................................................... 3,923 152,743
================= ===============
Total assets.................................................................................$ 10,331,683 $ 9,701,686
================= ===============
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Revolving credit facilities......................................................................$ 0 $ 0
Current maturities of long-term debt........................................................... 178,279 711,464
Current maturities of capital lease obligations................................................ 9,613 23,811
Accounts payable............................................................................... 272,793 412,933
Accrued liabilities and other liabilities...................................................... 398,325 250,714
----------------- ---------------
Total current liabilities.................................................................... 859,013 1,398,922
Bonds payable, and other long-term debt, net of current maturities............................... 412,367 46,815
Capital lease obligations, net of current portion................................................ 25,530 25,530
Deferred revenue................................................................................. 3,522 8,680
----------------- ---------------
Total liabilities............................................................................ 1,300,432 1,479,947
----------------- ---------------
Shareholders' equity:
Preferred stock, $1 par value; 2,000,000 shares authorized, none issued........................ - -
Common stock, $.01 par value; 10,000,000 shares authorized;....................................
3,711,883 issued........................................................................... 37,119 37,119
Additional paid-in-capital....................................................................... 9,140,293 8,946,293
Common stock held in treasury, 363,706 and 298,406 shares at cost................................ (1,282,953) (1,151,892)
Unearned ESOP compensation....................................................................... 0 0
Retained earnings................................................................................ 1,136,792 390,219
----------------- ---------------
Total shareholders' equity................................................................... 9,031,251 8,221,739
----------------- ---------------
Total liabilities and shareholders' equity...................................................$ 10,331,683 $ 9,701,686
================= ===============
</TABLE>
The accompanying notes are an integral part of the consolidated financial
statements.
3
<PAGE>
ARRHYTHMIA RESEARCH TECHNOLOGY, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
<TABLE>
<CAPTION>
Three Months Ended June 30, Six Months Ended June 30,
----------------------------------- ----------------------------------
2000 1999 2000 1999
---------------- ----------------- ---------------- ----------------
<S> <C> <C> <C> <C>
Net sales......................................$ 2,863,091 $ 2,922,771 $ 5,406,917 $ 5,364,454
Cost of sales.................................. 1,280,596 1,812,395 2,957,230 3,541,489
---------------- ----------------- ---------------- ----------------
Gross profit................................... 1,582,495 1,110,376 2,449,687 1,822,965
---------------- ----------------- ---------------- ----------------
Selling and marketing.......................... 23,617 75,772 129,197 146,370
General and administrative..................... 605,622 537,752 1,092,760 1,038,579
Research and development....................... 26,407 21,795 79,334 66,655
Amortization of goodwill....................... 32,473 32,473 64,945 65,575
---------------- ----------------- ---------------- ----------------
Total expenses................................. 688,119 667,792 1,366,236 1,317,179
---------------- ----------------- ---------------- ----------------
Income from operations......................... 894,376 442,584 1,083,451 505,786
Other (income) expense:
Interest expense ............................ 7,080 32,262 14,319 42,239
Other........................................ 59,454 71,784 87,559 107,657
---------------- ----------------- ---------------- ----------------
Income before income taxes .................... 827,842 338,538 981,573 355,890
Income taxes .................................. 183,000 141,156 235,000 159,639
---------------- ----------------- ---------------- ----------------
Net income ....................................$ 644,842 $ 197,382 $ 746,573 $ 196,251
================ ================= ================ ================
Net income per share - basic...................$ 0.19 $ 0.06 $ 0.22 $ 0.06
================ ================= ================ ================
Weighted average number of common
shares outstanding........................... 3,376,710 3,440,601 3,421,316 3,440,601
================ ================= ================ ================
Net income per share - dilutive................$ 0.18 $ 0.06 $ 0.21 $ 0.06
================ ================= ================ ================
Dilutive average number of common
equivalent shares outstanding................ 3,547,419 3,485,001 3,506,670 3,485,001
================ ================= ================ ================
</TABLE>
The accompanying notes are an integral part of the consolidated financial
statements.
4
<PAGE>
ARRHYTHMIA RESEARCH TECHNOLOGY, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY
(Unaudited)
<TABLE>
<CAPTION>
Retained
Additional Unearned Earnings
Common Shares Paid-in Treasury ESOP (Accumulated
Number Amount Capital Stock Compensation Deficit) Total
----------- -------- ----------- ------------ ------------ ----------- ------------
<S> <C> <C> <C> <C> <C> <C> <C>
December 31, 1997................. 3,563,101 36,792 8,909,307 (878,787) (82,134) 101,612 8,086,790
Treasury stock purchase........... (28,400) (34,297) (34,297)
ESOP payments..................... 42,857 42,857
Net income........................ (136,438) (136,438)
----------- -------- ----------- ------------ ------------ ----------- ------------
December 31, 1998................. 3,534,701 36,792 8,909,307 (913,084) (39,277) (34,826) 7,958,912
Issuance of common stock ......... 32,667 327 36,986 37,313
Treasury stock purchase........... (153,891) (238,808) (238,808)
ESOP payments..................... 39,277 39,277
Net income........................ 425,045 425,045
----------- -------- ----------- ------------ ------------ ----------- ------------
December 31, 1999................. 3,413,477 37,119 8,946,293 (1,151,892) 0 390,219 8,221,739
Treasury stock purchase........... (65,300) (131,061) (131,061)
Value of warrants with
bond renewal.................... 194,000 194,000
Net income........................ 746,573 746,573
----------- -------- ----------- ------------ ------------ ----------- ------------
June 30, 2000..................... 3,348,177 $ 37,119 $ 9,140,293 $ (1,282,953) $ 0 $ 1,136,792 $ 9,031,251
=========== ======== =========== ============ ============ =========== ============
</TABLE>
The accompanying notes are an integral part of the consolidated financial
statements.
5
<PAGE>
ARRHYTHMIA RESEARCH TECHNOLOGY, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
<TABLE>
<CAPTION>
Six Months Ended June 30,
------------------------------------
2000 1999
----------------- ----------------
<S> <C> <C>
Cash flows from operating activities:
Net income.................................................................................$ 746,573 $ 196,251
Adjustments to reconcile net income to net cash provided by operating
activities:
Depreciation............................................................................. 383,774 342,579
Amortization............................................................................. 82,315 87,099
Deferred income tax provision ........................................................... 177,000 -
Changes in assets and liabilities:
(Increase) Decrease in trade and other accounts receivable............................... (936,610) (663,323)
(Increase) Decrease in other current assets.............................................. (23,457) 16,355
(Increase) Decrease in inventories....................................................... (117,527) 509,749
Increase (Decrease) in accounts payable, accrued liabilities and other liabilities....... (21,348) 3,541
Increase (Decrease) in income taxes payable.............................................. 9,466 47,515
----------------- ----------------
Net cash provided by operating activities............................................... 300,186 539,766
----------------- ----------------
Cash flows from investing activities:
Capital expenditures, net of disposals..................................................... (151,321) (283,847)
Increase in assets for sale................................................................ (378,990) -
Deposits on capital equipment and other assets............................................. 148,820 (2,377)
Patent and software development expenditures............................................... (8,843) (70,592)
----------------- ----------------
Net cash used in investing activities.................................................... (390,334) (356,816)
----------------- ----------------
Cash flows from financing activities:
Increase in bonds payable due to amortization.............................................. 26,367 62,986
Reduction of unearned ESOP compensation.................................................... - 21,429
Purchases of treasury stock................................................................ (131,061) (79,410)
Principal payments on long-term debt, net.................................................. - (141,669)
----------------- ----------------
Net cash used in financing activities.................................................... (104,694) (136,664)
----------------- ----------------
Net increase (decrease) in cash and cash equivalents......................................... (194,842) 46,286
Cash and cash equivalents at beginning of period............................................. 455,674 557,533
----------------- ----------------
Cash and cash equivalents at end of period...................................................$ 260,832 $ 603,819
================= ================
</TABLE>
Supplemental Note: Non-cash flow items from financing activities
of $194,000 (bond discount and paid in capital).
The accompanying notes are an integral part of the consolidated financial
statements.
6
<PAGE>
SUPPLEMENTAL NOTES TO FINANCIAL STATEMENTS
The unaudited interim consolidated financial statements and related
notes have been prepared pursuant to the rules and regulations of the Securities
and Exchange Commission. Accordingly, certain information and footnote
disclosures normally included in financial statements prepared in accordance
with generally accepted accounting principles have been omitted pursuant to such
rules and regulations. The accompanying unaudited interim consolidated financial
statements and related notes should be read in conjunction with the consolidated
financial statements and notes thereto included in the Company's most recent
Form 10-K covering the year ended December 31, 1999.
The information furnished reflects, in the opinion of the management of
Arrhythmia Research Technology, Inc. ("ART"), all adjustments necessary for a
fair presentation of the financial results for the interim period presented.
Interim results are subject to year-end adjustments and audit by
independent certified public accountants.
INVENTORIES:
Inventories consist of the following as of:
<TABLE>
<CAPTION>
JUNE 30, DECEMBER 31,
2000 1999
--------------- ---------------
<S> <C> <C>
Raw materials............................................... $ 205,132 $ 252,237
Work-in-process............................................. 210,310 233,966
Finished goods.............................................. 1,245,302 1,054,814
--------------- ---------------
Total.................................................. 1,660,744 1,541,017
Allowance for slow-moving inventories....................... (460,700) (458,500)
--------------- ---------------
Total.................................................. $ 1,200,044 $ 1,082,517
=============== ===============
</TABLE>
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
LIQUIDITY AND CAPITAL RESOURCES
At June 30, 2000, the Company had working capital of approximately
$3,975,598 which included $1,000.000 of commission income from GE/Pruka that was
collected in July. At December 31, 1999, working capital was approximately
$2,174,000, which had been reduced by $580,000 of bonds payable classified in
2000 as non-current following a two-year extension of the maturity date of the
bonds. The Company has available $800,000 of borrowing under a working capital
line of credit with a bank, collateralized by accounts receivable and inventory,
which bears interest at the bank "base rate" (prime). The working capital line
of credit had no outstanding balance at June 30, 2000. The Company's lines of
credit are its primary source of operating funds and liquidity.
The Company renewed a $600,000 private placement bond, which
was due to mature May 31, 2000. The bondholders also accepted an extension until
May 31, 2002 for warrants to acquire 231,800 shares of the Company's stock at
$1.50 per share. The bonds are subordinated to the bank's line of credit, carry
an 11% interest rate and mature May 31, 2002.
Capital expenditures, net of disposals, for the first six months of
2000 were approximately $151,000 compared to $284,000 in 1999. Machinery and
equipment acquisitions to startup a new polymer line in early 2000 totaled
$379,000. The polymer line was discontinued in early 2000 and the assets held
for sale. In July, major components of this discontinued operation were sold
with no appreciable loss.
RESULTS OF OPERATIONS
TOTAL REVENUES for the second quarter of 2000 was $2,863,091 and net
income was $644,842. Included in these results was $1,000,000 of revenue
($760,000 net of tax) attributed to the termination of a commission agreement
with GE/Pruka. The commission agreement covering sales of Cardio Lab systems was
scheduled to expire on December 31, 2002, however, GE/Pruka negotiated to buy
out the remainder of the contract with no further obligations to either party.
Excluding the commissions from GE/Pruka in the second quarter for
both years, the revenue was $1,863,091 and the net (loss) was ($115,158) for
2000 compared to revenue of $2,593,625 and net income of $88,764 in 1999. The
majority of the $730,534 decline in sales occurred in Micron products of
sensors and snaps. This change was the result of customers building inventory
in the first quarter and reducing orders in the second quarter. Legal
expenses of $90,821 were incurred in the second quarter in connection with
the environmental investigation by the Attorney General's office of
Massachusetts. The company has been informed the investigation has concluded
with no adverse actions. The drop in net income
7
<PAGE>
due to lower sales was partially offset by savings from closing down a
startup polymer line in early 2000 and the contraction of operations in the
Texas facility.
For the six-month period ended June 30, the revenues and net income
were $5,406,917 and $746,573 for 2000 compared to $5,364,454 and $196,251 in
1999. Again excluding the commissions from GE/Pruka in both years, revenue
and net (loss) were $4,406,917 and $13,427 for 2000 compared to $5,109,435
and $27,938 in 1999. Two major Micron customers accounted for the lower
revenue, a portion is expected to be recovered in the second half of 2000.
Legal expenses of $121,710 were incurred in the six months ended June 30,
2000 in connection with the environmental investigation by the Attorney
General's office of Massachusetts. All significant legal costs associated
with the investigation have been expensed in the first six months of 2000.
Net income improved slightly due to cost savings at both the Texas and
Massachusetts operations and reduced Federal taxes due to the higher
utilization of deferred tax deductions as a result of the large prepayment of
commission income to terminate the GE/Pruka agreement.
Domestic and foreign sales for the second quarter and six months are as follows:
<TABLE>
<CAPTION>
SECOND QUARTER FIRST SIX MONTHS
2000 % 1999 % 2000 % 1999 %
---- - ---- - ---- - ---- -
<S> <C> <C> <C> <C> <C> <C> <C> <C>
Domestic..... $1,557,879 54 $1,262,910 43 $2,330,178 43 $2,506,713 47
Foreign...... 1,305,212 46 1,659,861 57 3,076,739 57 2,858,741 53
--------- --------- ---------- ---------
Total......... $2,863,091 100 $2,922,771 100 $5,406,917 100 $5,365,454 100
========== ==== ========== === ========== === ========== ===
</TABLE>
The higher percentage of foreign sales in 2000 compared to 1999
reflects the transfer of production of a major Micron customer who closed a
U.S. plant and moved it's volume into a Canadian plant. For six months in
1999, the U.S. plant had $347,639 included in domestic sales.
COST OF SALES as a percent of sales increased 5.1% for the second
quarter of 2000 compared to the second quarter of 1999, exclusive of the effect
of the CardioLab commissions from GE/Pruka. This was due to an $871,478 or 32%
drop in Micron Products sales resulting in significant unabsorbed manufacturing
overhead. For the six month periods, cost of sales improved by 2.2%.
SELLING AND MARKETING EXPENSES for the second quarter of 2000 are
$52,155 or 69% below those of 1999 reflecting recent cuts in direct sales staff
until a new generation of signal-averaging products is available for market
introduction.
RESEARCH & DEVELOPMENT EXPENSES in 2000 have increased approximately
20% over 1999 in an endeavor to accelerate the completion time and
competitiveness of new software applications for ART's signal-averaging
product.
GENERAL AND ADMINISTRATIVE EXPENSES were $605,622 for the second
quarter of 2000 compared to $537,752 for the second quarter of 1999 and
$1,092,760 for the six months of 2000 compared to $1,038,579 for the six
months of 1999. The increase are attributed to legal expenses of $90,821 in
the second quarter of 2000 and $121,710 for the six months of 2000. These
legal expenses were incurred in connection with the environmental
investigation by the Attorney General's office of Massachusetts. The Company
has been informed the investigation has concluded with no adverse actions.
All significant legal costs associated with the investigation have been
expensed in the first six months of 2000.
INCOME TAXES as a percent of income before taxes in the second
quarter were 22% for 2000 and 42% for 1999 and for the six months were 24%
for 2000 and 45% in 1999. At December 31, 1999, the Company had approximately
$2,243,000 in potential tax deductions which has a recorded tax asset value
of $424,000. The unplanned receipt of the commission income of $1,000,000 has
resulted in a higher utilization of the unused tax deductions and the current
tax provision has been reduced to reflect this favorable tax reduction in
2000.
8
<PAGE>
SAFE HARBOR UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995.
Any forward looking statements made herein are based on current expectations
of the Company that involves a number of risks and uncertainties and should not
be considered as guarantees of future performance. These statements are made
under the Safe Harbor Provisions of the Private Securities Litigation Reform Act
of 1995. The factors that could cause actual results to differ materially
include: interruptions or cancellation of existing contracts, impact of
competitive products and pricing, product demand and market acceptance risks,
the presence of competitors with greater financial resources than the Company,
product development and commercialization risks and an inability to arrange
additional debt or equity financing.
9
<PAGE>
PART II - OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS - In March 2000, Astro-Med, Inc. ("Astro-Med") filed
suit against ART in Superior Court of Kent County, Rhode Island (the "RI
Litigation) alleging breach of contract, book account and unjust enrichment. The
suit is based upon the purchase by ART of the K-3 hemodynamic monitoring system
product line from Astro-Med. In April 1997, ART and Astro-Med entered into an
Asset Purchase Agreement (the "Agreement"). In September 1999 ART ceased to make
payments to Astro-Med pursuant to the Agreement. Astro-Med claims that ART is
indebted to Astro-Med in the principal amount of $178,279, plus interest and
late fees.
ART has removed the RI Litigation to the United States District Court
for the District of Rhode Island and has filed a motion to dismiss. In July,
ART's motion to dismiss was denied. ART has filed a complaint and counter claim
for breach of warranty.
ITEM 2. CHANGES IN SECURITIES - NONE
ITEM 3. DEFAULTS UPON SENIOR SECURITIES - NONE
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS - NONE
ITEM 5. OTHER INFORMATION - NONE
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K - NONE
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
ARRHYTHMIA RESEARCH TECHNOLOGY, INC.
/s/ E.P. Marinos,
--------------------------------
Chairman of the Board
/s/ Richard A Campbell,
--------------------------------
Vice President of Finance
August 15, 2000
10
